|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu
W, Giri DD, Viale A, Olshen AB, Gerald WL and Massagué J: Genes
that mediate breast cancer metastasis to lung. Nature. 436:518–524.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhong B, Liu Q and Liu Y, Xiong X and Liu
Y: Expressions of STAT3, p-STAT3 and E-cadherin in colorectal
cancer and clinical implications. Zhonghua Wei Chang Wai Ke Za Zhi.
17:594–597. 2014.(In Chinese). PubMed/NCBI
|
|
4
|
Landskron G, De la Fuente M, Thuwajit P,
Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in
the tumor microenvironment. J Immunol Res. 2014:1491852014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heinrich PC, Behrmann I, Haan S, Hermanns
HM, Müller-Newen G and Schaper F: Principles of interleukin
(IL)-6-type cytokine signalling and its regulation. Biochem J.
374:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bromberg J and Darnell JE Jr: The role of
STATs in transcriptional control and their impact on cellular
function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal
transducer and activator of transcription-3, inflammation, and
cancer: How intimate is the relationship? Ann NY Acad Sci.
1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lin Q, Lai R, Chirieac LR, Li C, Thomazy
VA, Grammatikakis I, Rassidakis GZ, Zhang W, Fujio Y, Kunisada K,
et al: Constitutive activation of JAK3/STAT3 in colon carcinoma
tumors and cell lines: Inhibition of JAK3/STAT3 signaling induces
apoptosis and cell cycle arrest of colon carcinoma cells. Am J
Pathol. 167:969–980. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Turkson J: STAT proteins as novel targets
for cancer drug discovery. Expert Opin Ther Targets. 8:409–422.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nielsen DL, Palshof JA, Larsen FO, Jensen
BV and Pfeiffer P: A systematic review of salvage therapy to
patients with metastatic colorectal cancer previously treated with
fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.
Cancer Treat Rev. 40:701–715. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang S, Wu X, Tan M, Gong J, Tan W, Bian
B, Chen M and Wang Y: Fighting fire with fire: Poisonous Chinese
herbal medicine for cancer therapy. J Ethnopharmacol. 140:33–45.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Qi F, Li A, Inagaki Y, Gao J, Li J, Kokudo
N, Li XK and Tang W: Chinese herbal medicines as adjuvant treatment
during chemo- or radio-therapy for cancer. Biosci Trends.
4:297–307. 2010.PubMed/NCBI
|
|
13
|
Cheng HM, Li CC, Chen CY, Lo HY, Cheng WY,
Lee CH, Yang SZ, Wu SL, Hsiang CY and Ho TY: Application of
bioactivity database of Chinese herbal medicine on the therapeutic
prediction, drug development, and safety evaluation. J
Ethnopharmacol. 132:429–437. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei L, Chen Y, Lin J, Zhao J, Chen X, Xu
W, Liu X, Sferra TJ and Peng J: Scutellaria barbata D. Don
induces apoptosis of human colon carcinoma cell through activation
of the mitochondrion-dependent pathway. J Med Plant Res.
5:1962–1970. 2011.
|
|
15
|
Lin J, Chen Y, Cai Q, Wei L, Zhan Y, Shen
A, Sferra TJ and Peng J: Scutellaria barbata D. Don inhibits
colorectal cancer growth via suppression of multiple signaling
pathways. Integr Cancer Ther. 13:240–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei L, Lin J, Wu G, Xu W, Li H, Hong Z and
Peng J: Scutellaria barbata D. Don induces G1/S arrest via
modulation of p53 and Akt pathways in human colon carcinoma cells.
Oncol Rep. 29:1623–1628. 2013.PubMed/NCBI
|
|
17
|
Wei L, Lin J, Xu W, Cai Q, Shen A, Hong Z
and Peng J: Scutellaria barbata D. Don inhibits tumor
angiogenesis via suppression of Hedgehog pathway in a mouse model
of colorectal cancer. Int J Mol Sci. 13:9419–9430. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shen A, Chen Y, Hong F, Lin J, Wei L, Hong
Z, Sferra TJ and Peng J: Pien Tze Huang suppresses IL-6-inducible
STAT3 activation in human colon carcinoma cells through induction
of SOCS3. Oncol Rep. 28:2125–2130. 2012.PubMed/NCBI
|
|
19
|
Scurr M, Ladell K, Besneux M, Christian A,
Hockey T, Smart K, Bridgeman H, Hargest R, Phillips S, Davies M, et
al: Highly prevalent colorectal cancer-infiltrating LAP+
Foxp3− T cells exhibit more potent immunosuppressive
activity than Foxp3+ regulatory T cells. Mucosal
Immunol. 7:428–439. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
de Jong PR, Mo JH, Harris AR, Lee J and
Raz E: STAT3: An anti-invasive factor in colorectal cancer. Cancers
(Basel). 6:1394–1407. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sabatino L, Pancione M, Votino C,
Colangelo T, Lupo A, Novellino E, Lavecchia A and Colantuoni V:
Emerging role of the β-catenin-PPARγ axis in the pathogenesis of
colorectal cancer. World J Gastroenterol. 20:7137–7151. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pandurangan AK: Potential targets for
prevention of colorectal cancer: A focus on PI3K/Akt/mTOR and Wnt
pathways. Asian Pac J Cancer Prev. 14:2201–2205. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Vaiopoulos AG, Athanasoula KC and
Papavassiliou AG: NF-κB in colorectal cancer. J Mol Med Berl.
91:1029–1037. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Boos G and Stopper H: Genotoxicity of
several clinically used topoisomerase II inhibitors. Toxicol Lett.
116:7–16. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li L and Leung PS: Use of herbal medicines
and natural products: An alternative approach to overcoming the
apoptotic resistance of pancreatic cancer. Int J Biochem Cell Biol.
53:224–236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
|
27
|
Yang X, Zhang F, Wang Y, Cai M, Wang Q,
Guo Q, Li Z and Hu R: Oroxylin A inhibits colitis-associated
carcinogenesis through modulating the IL-6/STAT3 signaling pathway.
Inflamm Bowel Dis. 19:1990–2000. 2013.PubMed/NCBI
|
|
28
|
Lim S and Kaldis P: Cdks, cyclins and
CKIs: Roles beyond cell cycle regulation. Development.
140:3079–3093. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin J, Chen Y, Wei L, Chen X, Xu W, Hong
Z, Sferra TJ and Peng J: Hedyotis diffusa Willd extracts
induces apoptosis via activation of the mitochondrion-dependent
pathway in human colon carcinoma cells. Int J Oncol. 37:1331–1338.
2010.PubMed/NCBI
|
